{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"The proportion of patients who achieve progression free at 2 years will be compared to the rate published for the high risk SMM. By the Mayo Clinic model for risk factors, the median time to progression for patients with high risk SMM was only 1.9 years. Therefore, we assume that, a 2-years progression-free rate of 50% will not be considered promising and a true progression free rate of 75% or higher will be considered promising.","groups":[{"description":"* Cycles 1-9\n\n  * Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle\n  * Lenalidomide is administered orally on days 1-21 on a 28 days cycle\n  * Dexamethasone is administered orally on days 1, 8, 15, 22 on a 28 days cycle\n* Cycle 10-24\n\n  * Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle\n  * Lenalidomide is administered orally on days 1-21 on a 28 days cycle\n* Supportive measures consistent with optimal patient care may be given throughout the study\n\nIxazomib: Oral, proteasome inhibitor\n\nLenalidomide: Oral, immunomodulatory agent\n\nDexamethasone: Oral, steroid","id":"OG000","title":"Ixazomib"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"2 years","title":"Proportion Of High Risk SMM Patients Who Are Progression Free 2 Years After Receiving IRD Combination Therapy","type":"PRIMARY","unitOfMeasure":"Participants"}